What was recalled
This page synthesizes the algae-sourced omega-3 fatty acid framework in commercial pet food, with particular focus on the vegan formulation context and the EPA gap that DHA-dominant microalgae sources create. Long-chain omega-3 fatty acids EPA (eicosapentaenoic acid, 20:5n-3) and DHA (docosahexaenoic acid, 22:6n-3) are physiologically active in companion animals through multiple framework: EPA-derived eicosanoids compete with arachidonic acid (omega-6) derived eicosanoids in inflammatory cascades, with EPA-derived 3-series prostaglandins, 5-series leukotrienes, and 3-series thromboxanes generally less inflammatory than their omega-6-derived 2-series and 4-series counterparts; DHA-enriched cell membrane composition is critical for neurological development (brain DHA content is approximately 25% of total fatty acids), retinal photoreceptor function, and cell membrane fluidity generally; cardiovascular framework including blood pressure modulation, triglyceride reduction, and antiarrhythmic effect; and immune modulation through specialized pro-resolving mediators (resolvins, protectins, maresins) derived from EPA and DHA.
The dominant commercial source for pet food omega-3 supplementation is fish oil, typically from anchovy, sardine, menhaden, salmon, or pollack source fisheries. Fish oil provides both EPA and DHA in source-fish-dependent ratios: anchovy and sardine oil typically deliver 18% EPA and 12% DHA, menhaden oil 13% EPA and 9% DHA, salmon oil 8-12% EPA and 5-8% DHA depending on processing and source. The complete omega-3 supplementation profile is well-supported across the commercial pet food category, with brand-level disclosure of source-fish identification and EPA/DHA concentration ratios available for most established manufacturers.
Vegan pet food formulations cannot use fish-derived omega-3 sources and have turned to microalgae-derived omega-3 supplementation. The major commercial microalgae sources are Schizochytrium sp. (multiple commercial strains, with DHA typically 30-40% of total fatty acids and EPA typically under 2%; commercial production by DSM, Veramaris, Cellana, and others), Crypthecodinium cohnii (DHA-dominant marine dinoflagellate, with DHA typically 40-50% of total fatty acids and minimal EPA; commercial production primarily by DSM under the life'sDHA brand), and the less commercially developed Nannochloropsis sp. (EPA-rich marine microalgae, with EPA typically 20-30% of total fatty acids but lower commercial production scale). The microalgae DHA framework has been well-established in human infant formula (since approximately 2002) and has expanded into vegan and vegetarian pet food formulations and human dietary supplements. The EPA-source microalgae are commercially less developed and produce substantially smaller EPA volumes than fish-oil EPA supply.
Why it was recalled
The structural concerns have three layers. Layer one — EPA gap in DHA-only vegan formulations: vegan pet food formulations using only Schizochytrium or Crypthecodinium algal DHA may have substantially inadequate EPA without separate Nannochloropsis or other EPA-source supplementation. The EPA functional framework (anti-inflammatory eicosanoid production, specialized pro-resolving mediator synthesis, cardiovascular and immune effects) is not adequately supported by DHA-only supplementation, since DHA does not significantly retro-convert to EPA in companion animals. The framework is structurally similar to the alpha-linolenic acid (ALA) to EPA conversion limitation that has been documented in carnivores generally — cats have essentially absent ALA-to-EPA conversion capacity, and dogs have very limited capacity. Vegan pet food formulations relying on flax-oil ALA for EPA conversion (covered separately on our forthcoming ALA conversion controversy pages) face a parallel limitation.
Layer two — brand-level omega-3 disclosure in vegan pet food formulations is uneven: commercial vegan pet food formulations vary substantially in algal omega-3 inclusion: some formulations include only Schizochytrium algal DHA (no significant EPA); some include flax oil for ALA (with very limited EPA / DHA conversion in companion animals); some include Nannochloropsis or other EPA-source algae; some include comprehensive algal omega-3 (DHA + EPA from multiple algal sources). Brand-level marketing claims around vegan omega-3 supplementation rarely distinguish DHA-only from EPA-containing supplementation, and pet owners cannot easily evaluate the functional adequacy of the omega-3 framework from ingredient labeling alone.
Layer three — vegan pet food framework has additional nutritional concerns beyond omega-3: the broader vegan pet food framework involves additional nutritional considerations beyond the algal omega-3 framework: feline taurine essentiality (covered on our synthetic taurine controversy page), feline arginine essentiality (covered on our arginine carnivore essential page), feline obligate dietary niacin (covered on our tryptophan-niacin endogenous synthesis page), vitamin A retinol versus beta-carotene (with feline limited conversion capacity), vitamin D source-form considerations, and complete amino acid profile from plant-protein sources requiring methionine supplementation. Vegan feline pet food in particular requires comprehensive nutritional formulation expertise; vegan canine pet food has somewhat fewer obligate dietary essentials but still requires careful formulation for amino acid completeness and omega-3 framework.
Health risks for your pet
Algae-sourced DHA at typical pet supplement and pet food inclusion rates is well-tolerated and safe for dogs and cats. The microalgae production framework has substantial commercial history (since approximately 2002 in human infant formula and since the mid-2010s in pet food applications) with favorable safety profile in commercial production. Documented concerns are limited: theoretical heavy metal contamination from microalgae cultivation water (essentially absent in commercial controlled-cultivation production but a theoretical concern in bulk-sourced algae); occasional product withdrawals related to oxidation of algal oil products (parallel to fish-oil rancidity framework); and limited concerns about omega-3 supplementation interaction with anticoagulant medications at very high doses.
The pet-food-specific concern is the EPA gap in DHA-only vegan formulations. Pet owners selecting vegan pet food formulations with omega-3 framework consideration should look for explicit disclosure of algal source (Schizochytrium, Crypthecodinium, Nannochloropsis, or comprehensive multi-source), DHA and EPA concentration ratios in the algal supplementation, and overall EPA + DHA inclusion rate per serving. Brand-level disclosure varies substantially across the vegan pet food category. For pets with specific clinical indications for omega-3 supplementation (osteoarthritis, dermatitis, cardiovascular disease), the EPA framework is generally more clinically validated than the DHA-only framework in companion-animal evidence; vegan formulations relying on DHA-only algal supplementation may not deliver the same clinical benefit as fish-oil-supplemented or comprehensive multi-source algal supplementation.
What to do if you bought affected product
Pet owners can interpret algae-sourced omega-3 pet food framework appropriately through several practical approaches: (1) recognize that DHA-only algal supplementation does not deliver EPA framework — Schizochytrium and Crypthecodinium microalgae are dominant commercial algal DHA sources with minimal EPA content; DHA does not significantly retro-convert to EPA in companion animals, and vegan pet food formulations using only DHA-source algae may have inadequate EPA without separate Nannochloropsis or other EPA-source supplementation; (2) request algal source and DHA/EPA ratio disclosure from brand customer service for vegan pet food formulations — brands with comprehensive multi-source algal supplementation (DHA + EPA) typically promote the framework prominently; (3) understand that vegan pet food framework involves broader nutritional considerations beyond omega-3 — feline taurine, arginine, niacin, vitamin A, and complete amino acid framework all require careful formulation in vegan feline pet food; vegan canine pet food has somewhat fewer obligate dietary essentials but still requires careful formulation; (4) for pets with specific clinical indications for omega-3 supplementation (osteoarthritis, dermatitis, cardiovascular disease, immune modulation), recognize that the EPA framework is generally more clinically validated than the DHA-only framework in companion-animal evidence; (5) discuss vegan feline pet food framework with veterinary nutritionist, ideally board-certified veterinary nutritionist (ACVIM-Nutrition), particularly for prolonged use as sole nutritional source — the comprehensive feline obligate dietary essentials framework warrants professional formulation guidance; (6) consider supplementary algal omega-3 (commercial vegan EPA + DHA supplements) for pets on vegan pet food formulations with DHA-only algal supplementation; the supplement framework can address the EPA gap without requiring formulation switch.
How this affects KibbleIQ’s grade
The KibbleIQ rubric v15 does not currently differentiate algal omega-3 source framework at the brand level per our published methodology, since algal omega-3 inclusion is currently a minority pet food framework concentrated in vegan and vegetarian formulations. Future rubric extension under consideration: brands with comprehensive multi-source algal supplementation (DHA + EPA) and explicit source disclosure would warrant favorable scoring weight as transparency signal; brands using only DHA-source algae in vegan formulations without addressing the EPA gap would warrant scoring caution particularly when marketed for clinical indications (osteoarthritis, dermatitis, immune modulation). The broader omega-3 source framework is covered on our omega-3 EPA DHA source comparison and fish oil EPA DHA ratio controversy pages. For now, our recommendation: recognize the EPA gap in DHA-only algal supplementation, request brand-level source and ratio disclosure for vegan formulations, and discuss vegan pet food framework with veterinary nutritionist particularly for vegan feline formulations.